Clinical Trial COGACNS0821


ACNS0821 - Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial

Principal Investigator(s)

Adam Esbenshade


  • Protocol No. COGACNS0821
  • Open Date: 10/08/2011
  • Staging: Phase II
  • Age Group: Children
  • Scope: National
  • Objective: To compare the overall survival (OS) of subjects receiving the combination of temozolomide and irinotecan with that of subjects receiving temozolomide, irinotecan and bevacizumab for recurrent medulloblastoma (MB)/PNET of childhood.
  • Disease Sites: Neuro-Oncology; Pediatrics
  • Therapies: Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Avastin; Bevacizumab; Camptosar (Irinotecan); TMZ; Temodar; Temozolomide
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01217437
  • Secondary Protocol No: ACNS0821



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.